Vedanta Biosciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor conferences:

Wells Fargo Virtual Private Biotech Symposium
Date: Monday, May 6, 2024
Virtual 1x1 meetings only

The Citizens JMP Life Sciences Conference
Dates: May 13-14, 2024
Presentation: Tuesday, May 14 at 12:30 p.m. ET
Location: New York Hilton Midtown, New York, NY

About Vedanta Biosciences

Vedanta Biosciences is a clinical-stage biopharmaceutical company developing medicines for the treatment of gastrointestinal diseases. The company’s lead assets are potential first-in-class oral therapies – VE303, soon to begin a Phase 3 registrational trial for prevention of recurrent C. difficile infection, and VE202, in a Phase 2 trial for treatment of ulcerative colitis. Vedanta’s pipeline has been built using the company’s industry-leading product engine for the development of therapies based on defined consortia of bacteria grown from pure clonal cell banks. The product engine, supported by broad foundational intellectual property, includes one of the largest libraries of bacteria isolated from the human microbiome, vast clinical datasets, proprietary capabilities in consortium design, and end-to-end CGMP manufacturing capabilities at commercial launch scale.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240429150086/en/

Media
Nichole Bobbyn
+1 774 278 8273
[email protected]

Investors
Chris Brinzey
+ 1 617 835 9304
[email protected]

Source: Vedanta Biosciences

You May Also Be Interested In

• OpenSea Adds Support for Solana NFTs, Extending Its Marketplace
• Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines
• Elevate Service Group Reports Record Q2-2026 Revenue of $20.5 Million as Operating Platform Continues to Scale